Alternating hemiplegia of childhood (AHC) is a rare neurological disorder that usually manifests before 18 months of age and is characterized by recurrent, alternating episodes of hemiparesis with variable frequency and can last from a few minutes to several days. We present a case of AHC in a little girl carrying a sporadic mutation in the ATP1A3 gene (p.Glu815Lys) refractory to flunarizine and non-compliant to topiramate due to adverse effects treated with oral compound of adenosine-5′-triphosphate (ATP) capsules. Outcome was evaluated through the follow-up and side effects and safety were monitored regularly. Compounded drug showed effectiveness and safety. Indeed, during the four-year follow-up, with the dose of adenosine-5′-triphosphate gradually increasing up to 21 mg/kg, the patient showed a substantial benefit in controlling the frequency and duration of hemiplegic episodes and an improvement in neurological deterioration.
Oral ATP treatment in alternating hemiplegia of childhood: a case report and review / Carrozzi, Marco; Morelli, Maria Elisa; Cirino, Mario; Maestro, Alessandra; Paternuosto, Gilda; Benericetti, Giulia; Bennati, Giada; Bin, Maura; Flamigni, Anna; Pigato, Federico; Maximova, Natalia; Barbi, Egidio; Zanon, Davide. - In: FRONTIERS IN MEDICINE. - ISSN 2296-858X. - ELETTRONICO. - 11:(2025), pp. 1433217."-"-1433217."-". [10.3389/fmed.2024.1433217]
Oral ATP treatment in alternating hemiplegia of childhood: a case report and review
Paternuosto, Gilda;Bennati, Giada;Maximova, Natalia;Barbi, EgidioPenultimo
;Zanon, DavideUltimo
2025-01-01
Abstract
Alternating hemiplegia of childhood (AHC) is a rare neurological disorder that usually manifests before 18 months of age and is characterized by recurrent, alternating episodes of hemiparesis with variable frequency and can last from a few minutes to several days. We present a case of AHC in a little girl carrying a sporadic mutation in the ATP1A3 gene (p.Glu815Lys) refractory to flunarizine and non-compliant to topiramate due to adverse effects treated with oral compound of adenosine-5′-triphosphate (ATP) capsules. Outcome was evaluated through the follow-up and side effects and safety were monitored regularly. Compounded drug showed effectiveness and safety. Indeed, during the four-year follow-up, with the dose of adenosine-5′-triphosphate gradually increasing up to 21 mg/kg, the patient showed a substantial benefit in controlling the frequency and duration of hemiplegic episodes and an improvement in neurological deterioration.| File | Dimensione | Formato | |
|---|---|---|---|
|
oral atp.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
1.26 MB
Formato
Adobe PDF
|
1.26 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


